Pipeline Advancements And International Expansion Will Shape Future Markets

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

12 Sep 24

Updated

25 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-18.8%

7D

4.3%

Loading

1Y

-18.8%

7D

4.3%

You can edit this narrative until Nov 26 12:05 PM. Then, changes will post as Updates.

Author's Valuation

US$9.3943.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 25 Nov 25

Fair value Decreased 6.69%

MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties Expansion

Analysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.

Shared on 11 Nov 25

Fair value Decreased 4.81%

MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-Rating

MannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.

Shared on 27 Aug 25

Fair value Increased 14%

Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.

Shared on 01 May 25

Fair value Decreased 1.89%

Shared on 23 Apr 25

Fair value Decreased 12%

Shared on 17 Apr 25

Fair value Increased 2.79%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 4.11%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 11 Mar 25

Fair value Increased 2.74%

AnalystConsensusTarget has decreased revenue growth from 15.7% to 12.0%, decreased profit margin from 28.3% to 23.5% and increased future PE multiple from 30.8x to 47.4x.

AnalystConsensusTarget Fair Value

US$9.39

43.0% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

16.36%

Biotech revenue growth rate

8.93%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.27%

Calculation

US$94.99m

Earnings '28

x

38.65x

PE Ratio '28

=

US$3.67b

Market Cap '28

US$3.67b

Market Cap '28

/

317.75m

No. shares '28

=

US$11.55

Share Price '28

US$11.55 Share Price '28

Discounted to 2025 @ 7.25% p.a.

=

US$9.37

Fair Value '25